BioHarvest Sciences Inc. (NASDAQ:BHST) Sees Significant Decline in Short Interest

BioHarvest Sciences Inc. (NASDAQ:BHST) saw a large decline in short interest in December. As of December 15th, there was short interest totaling 33,198 shares, a decline of 52.9% from the November 30th total of 70,472 shares. Based on an average daily trading volume, of 64,612 shares, the short-interest ratio is currently 0.5 days. Currently, 0.2% of the shares of the stock are short sold. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 64,612 shares, the short-interest ratio is currently 0.5 days.

BioHarvest Sciences Trading Down 5.0%

Shares of NASDAQ BHST traded down $0.28 during mid-day trading on Friday, hitting $5.33. The stock had a trading volume of 28,864 shares, compared to its average volume of 59,806. The firm has a market cap of $87.52 million, a P/E ratio of -7.84 and a beta of 0.95. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.02 and a current ratio of 1.35. The business has a 50 day moving average price of $7.29 and a two-hundred day moving average price of $8.02. BioHarvest Sciences has a 1 year low of $4.72 and a 1 year high of $12.80.

BioHarvest Sciences (NASDAQ:BHST) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.14) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.14). BioHarvest Sciences had a negative net margin of 36.33% and a negative return on equity of 1,041.86%. The business had revenue of $9.07 million for the quarter, compared to analysts’ expectations of $9.11 million. On average, equities analysts anticipate that BioHarvest Sciences will post -0.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on BHST shares. Wall Street Zen upgraded BioHarvest Sciences to a “hold” rating in a research report on Saturday, October 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioHarvest Sciences in a research report on Monday. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, BioHarvest Sciences presently has an average rating of “Hold” and an average price target of $14.50.

Hedge Funds Weigh In On BioHarvest Sciences

An institutional investor recently raised its position in BioHarvest Sciences stock. True North Advisors LLC boosted its holdings in shares of BioHarvest Sciences Inc. (NASDAQ:BHST) by 676.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 168,013 shares of the company’s stock after buying an additional 146,365 shares during the quarter. True North Advisors LLC owned 1.02% of BioHarvest Sciences worth $1,581,000 as of its most recent SEC filing.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.